UCB Pharma, Slough, SL1 3WE, UK.
GlaxoSmithKline, Stevenage, SG1 2NY, UK.
Nat Commun. 2021 Jan 25;12(1):582. doi: 10.1038/s41467-020-20828-3.
Tumour necrosis factor (TNF) is a trimeric protein which signals through two membrane receptors, TNFR1 and TNFR2. Previously, we identified small molecules that inhibit human TNF by stabilising a distorted trimer and reduce the number of receptors bound to TNF from three to two. Here we present a biochemical and structural characterisation of the small molecule-stabilised TNF-TNFR1 complex, providing insights into how a distorted TNF trimer can alter signalling function. We demonstrate that the inhibitors reduce the binding affinity of TNF to the third TNFR1 molecule. In support of this, we show by X-ray crystallography that the inhibitor-bound, distorted, TNF trimer forms a complex with a dimer of TNFR1 molecules. This observation, along with data from a solution-based network assembly assay, leads us to suggest a model for TNF signalling based on TNF-TNFR1 clusters, which are disrupted by small molecule inhibitors.
肿瘤坏死因子(TNF)是一种三聚体蛋白,通过两种膜受体 TNFR1 和 TNFR2 信号传递。此前,我们发现了一些小分子,它们通过稳定扭曲的三聚体来抑制人 TNF,并将与 TNF 结合的受体数量从三个减少到两个。在这里,我们对小分子稳定的 TNF-TNFR1 复合物进行了生化和结构表征,深入了解扭曲的 TNF 三聚体如何改变信号传递功能。我们证明抑制剂降低了 TNF 与第三个 TNFR1 分子的结合亲和力。为了支持这一点,我们通过 X 射线晶体学显示,与抑制剂结合的扭曲的 TNF 三聚体与 TNFR1 分子的二聚体形成复合物。这一观察结果,以及来自基于溶液的网络组装测定的数据,使我们提出了一个基于 TNF-TNFR1 簇的 TNF 信号模型,该模型被小分子抑制剂破坏。